Concentric files for $69m IPO (initial public offering):
This article was originally published in Clinica
Executive Summary
Blood clot removal technology specialist Concentric Medical is looking to boost sales and marketing of its Merci retrieval system with proceeds from an initial public offering of common stock. The Mountain View, California-based company aims to raise $69m in the offering, $30m of which will be spent on commercialising its key product. The remainder will be used for R&D, regulatory activities and general corporate purposes. Merci is a minimally-invasive, catheter-based system, designed to restore blood flow in large vessel ischemic stroke patients and help minimise injury to the brain. According to Concentric, Merci was effective in restoring blood flow to 55% of ischemic stroke patients in a recent trial.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.